FDA approves Infant Bacterial Therapeutics’ request for a new orphan drug designation

Building upon Infant Bacterial Therapeutics AB’s (IBT) unique expertise in developing treatment solutions for preterm infants, IBT is at an early stage of investigating the possibilities of developing a drug to prevent retinopathy of prematurity, a growing and serious condition that often leads to blindness among prematurely born babies. The FDA granted orphan drug designation for IBT’s product on Sep 20th .

Go here to read the rest:
FDA approves Infant Bacterial Therapeutics' request for a new orphan drug designation